Shengchen Liu1, Reinard Iskandar1, Wen Chen1, Jie Zhang1, Yifei Wang1, Xin Chen2, Fei Xiang3. 1. Department of Thoracic and Cardiovascular Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China. 2. Department of Thoracic and Cardiovascular Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China. Electronic address: stevecx@njmu.edu.cn. 3. Department of Thoracic and Cardiovascular Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China. Electronic address: jackie-xf@163.com.
Abstract
BACKGROUND: Despite their importance, the current clinical biomarkers of chronic heart failure have limitations. In this study, soluble glycoprotein 130 (sgp130), heat shock protein 27 (hsp27), dipeptidyl peptidase IV (dpp4) and cathepsin S (CTSS) were tested for their potential as novel biomarkers for diagnosing chronic heart failure (CHF) with preserved ejection fraction. METHODS: We compared the circulating levels of sgp130, hsp27, dpp4, and cathepsin S in patients with CHF with preserved ejection fraction (n=50) and in controls (n=50), determined how well these candidate biomarkers distinguish patients with CHF from controls, and assessed whether these candidates are superior to N-terminal pro brain natriuretic peptide (NT-pro-BNP) as diagnostic tools. RESULTS: After adjusting for clinical covariates, patients with CHF showed significantly higher mean concentrations of sgp130 (317.38pg/ml vs. 215.90 pg/ml), hsp27 (2601.02 pg/ml vs. 923.61 pg/ml) and NT-pro-BNP (982.35 pg/ml vs. 331.99 pg/ml), but not dpp4 (6930.9 4pg/ml vs. 7081.37 pg/ml) or CTSS (1050.46 pg/ml vs. 984.96 pg/ml), than did controls. In the receiver operating characteristic curve analysis, hsp27 showed the most notable difference between CHF patients and controls, with the largest area under the curve (AUC) (0.920); the AUC values for sgp130 and NT-pro-BNP were 0.877 and 0.882, respectively. CONCLUSIONS: Soluble glycoprotein 130 and hsp27 are novel candidate biomarkers for diagnosing CHF with preserved ejection fraction and thus warrant further investigation; neither dpp4 nor CTSS showed promise as biomarkers of CHF.
BACKGROUND: Despite their importance, the current clinical biomarkers of chronic heart failure have limitations. In this study, soluble glycoprotein 130 (sgp130), heat shock protein 27 (hsp27), dipeptidyl peptidase IV (dpp4) and cathepsin S (CTSS) were tested for their potential as novel biomarkers for diagnosing chronic heart failure (CHF) with preserved ejection fraction. METHODS: We compared the circulating levels of sgp130, hsp27, dpp4, and cathepsin S in patients with CHF with preserved ejection fraction (n=50) and in controls (n=50), determined how well these candidate biomarkers distinguish patients with CHF from controls, and assessed whether these candidates are superior to N-terminal pro brain natriuretic peptide (NT-pro-BNP) as diagnostic tools. RESULTS: After adjusting for clinical covariates, patients with CHF showed significantly higher mean concentrations of sgp130 (317.38pg/ml vs. 215.90 pg/ml), hsp27 (2601.02 pg/ml vs. 923.61 pg/ml) and NT-pro-BNP (982.35 pg/ml vs. 331.99 pg/ml), but not dpp4 (6930.9 4pg/ml vs. 7081.37 pg/ml) or CTSS (1050.46 pg/ml vs. 984.96 pg/ml), than did controls. In the receiver operating characteristic curve analysis, hsp27 showed the most notable difference between CHFpatients and controls, with the largest area under the curve (AUC) (0.920); the AUC values for sgp130 and NT-pro-BNP were 0.877 and 0.882, respectively. CONCLUSIONS: Soluble glycoprotein 130 and hsp27 are novel candidate biomarkers for diagnosing CHF with preserved ejection fraction and thus warrant further investigation; neither dpp4 nor CTSS showed promise as biomarkers of CHF.
Authors: Chester L Drum; Warren K Y Tan; Siew-Pang Chan; Leroy S Pakkiri; Jenny P C Chong; Oi-Wah Liew; Tze-Pin Ng; Lieng-Hsi Ling; David Sim; Kui-Toh G Leong; Daniel P S Yeo; Hean-Yee Ong; Fazlur Jaufeerally; Raymond C C Wong; Ping Chai; Adrian F Low; Pia Davidsson; Mathias Liljeblad; Ann-Sofi Söderling; Li-Ming Gan; Ratan V Bhat; Kristy Purnamawati; Carolyn S P Lam; A Mark Richards Journal: J Am Heart Assoc Date: 2017-06-13 Impact factor: 5.501
Authors: Michiel T H M Henkens; Sharon Remmelzwaal; Emma L Robinson; Adriana J van Ballegooijen; Arantxa Barandiarán Aizpurua; Job A J Verdonschot; Anne G Raafs; Jerremy Weerts; Mark R Hazebroek; Sandra Sanders-van Wijk; M Louis Handoko; Hester M den Ruijter; Carolyn S P Lam; Rudolf A de Boer; Walter J Paulus; Vanessa P M van Empel; Rein Vos; Hans-Peter Brunner-La Rocca; Joline W J Beulens; Stephane R B Heymans Journal: Eur J Heart Fail Date: 2020-08-07 Impact factor: 15.534
Authors: Raffaele Altara; Fouad A Zouein; Rita Dias Brandão; Saeed N Bajestani; Alessandro Cataliotti; George W Booz Journal: Front Cardiovasc Med Date: 2018-02-21
Authors: Sharon Remmelzwaal; Adriana J van Ballegooijen; Linda J Schoonmade; Elisa Dal Canto; M Louis Handoko; Michiel T H M Henkens; Vanessa van Empel; Stephane R B Heymans; Joline W J Beulens Journal: BMC Med Date: 2020-10-30 Impact factor: 8.775